4.8 Article

Neuro-Sjogren: Peripheral Neuropathy With Limb Weakness in Sjogren's Syndrome

Journal

FRONTIERS IN IMMUNOLOGY
Volume 10, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2019.01600

Keywords

Sjogren's syndrome; Neuro-Sjogren; neuropathy; chronic inflammatory demyelinating polyneuropathy; motoneuron disease

Categories

Ask authors/readers for more resources

Objective: Sjogren's syndrome is a heterogeneous inflammatory disorder frequently involving peripheral nerves with a wide spectrum of sensory modalities and distribution patterns. The objective of this cross-sectional study was to determine characteristics of Sjogren's syndrome as a cause for severe neuropathy with limb weakness. Methods: One hundred and eighty four patients with polyneuropathy associated with limb weakness underwent routine diagnostics including investigations for Sjogren's syndrome. Forty-four patients with Sjogren's syndrome (ACR-EULAR classification criteria) and severe neuropathy were identified. Results: Sjogren's syndrome was found at a median age of 63 years and the gender distribution showed a balanced female-male ratio of 1 :1 . Anti-SSA(Ro) antibodies were detected in 48% while seronegative patients were diagnosed with Sjogren's syndrome based on sialadenitis on minor salivary gland biopsy with a focus score >= 1. The majority of patients (93%) were diagnosed with Sjogren's syndrome after neurological symptoms appeared. Limbs were symmetrically involved in 84% of patients (57% tetraparesis, 27% paraparesis). Sensory function was not affected in 11% of patients indicating that Sjogren's syndrome associated neuropathy can present as a pure motor syndrome. Electrophysiological measurements did not reveal pathognomonic findings (23% demyelinating pattern, 36% axonal pattern, 41% both demyelinating and axonal damage signs). More than half of our patients fulfilled the European Federation of Neurological Societies (EFNS) diagnostic criteria for CIDP indicating that distinction between Neuro-Sjogren and other causes of neuropathy such as CIDP is challenging. Interpretation: Our findings show that severe neuropathy with limb weakness is often associated with Sjogren's syndrome. This is of great importance in identifying and understanding the causes of immune mediated polyneuropathy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Immunology

Clinical decision making is improved by BioFire Pneumonia Plus in suspected lower respiratory tract infection after lung transplantation: Results of the prospective DBATE-IT* study

Moritz Z. Kayser, Benjamin Seeliger, Christina Valtin, Jan Fuge, Stefan Ziesing, Tobias Welte, Mathias W. Pletz, Patrick Chhatwal, Jens Gottlieb

Summary: The study showed that BFPPp offered faster test results compared to conventional tests, which led to quicker clinical decisions. BFPPp demonstrated high accuracy in diagnosing viral LRTI, non-viral LRTI, and combined viral and non-viral LRTI. Additionally, preliminary therapies based on BFPPp results were upheld in 90% of cases.

TRANSPLANT INFECTIOUS DISEASE (2022)

Article Rheumatology

Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study

Alessandra Bettiol, Maria Letizia Urban, Lorenzo Dagna, Vincent Cottin, Franco Franceschini, Stefano Del Giacco, Franco Schiavon, Thomas Neumann, Giuseppe Lopalco, Pavel Novikov, Chiara Baldini, Carlo Lombardi, Alvise Berti, Federico Alberici, Marco Folci, Simone Negrini, Renato Alberto Sinico, Luca Quartuccio, Claudio Lunardi, Paola Parronchi, Frank Moosig, Georgina Espigol-Frigole, Jan Schroeder, Anna Luise Kernder, Sara Monti, Ettore Silvagni, Claudia Crimi, Francesco Cinetto, Paolo Fraticelli, Dario Roccatello, Angelo Vacca, Aladdin J. Mohammad, Bernhard Hellmich, Maxime Samson, Elena Bargagli, Jan Willem Cohen Tervaert, Camillo Ribi, Davide Fiori, Federica Bello, Filippo Fagni, Luca Moroni, Giuseppe Alvise Ramirez, Mouhamad Nasser, Chiara Marvisi, Paola Toniati, Davide Firinu, Roberto Padoan, Allyson Egan, Benjamin Seeliger, Florenzo Iannone, Carlo Salvarani, David Jayne, Domenico Prisco, Augusto Vaglio, Giacomo Emmi

Summary: Mepolizumab at both 100 mg every 4 weeks and 300 mg every 4 weeks proved effective in treating EGPA, with no significant difference between the two doses. Complete response rates reached 30.4% at 12 months and 35.7% at 24 months, with some patients experiencing exacerbations in asthma and ENT.

ARTHRITIS & RHEUMATOLOGY (2022)

Letter Critical Care Medicine

It takes two to bleed: anticoagulation intensity and the host's vascular susceptibility

Benjamin Seeliger, Pedro David Wendel-Garcia, Klaus Stahl, Christian Bode, Sascha David

INTENSIVE CARE MEDICINE (2022)

Article Clinical Neurology

Public health situation of CIDP patients in nine German centers-neuritis network Germany

Anna Lena Fisse, Jeremias Motte, Thomas Grueter, Felix Kohle, Cornelius Kronlage, Jan-Hendrik Stahl, Natalie Winter, Tabea Seeliger, Stefan Gingele, Frauke Stascheit, Benjamin Hotter, Juliane Klehmet, Karsten Kummer, Elena K. Enax-Krumova, Dietrich Sturm, Thomas Skripuletz, Jens Schmidt, Min-Suk Yoon, Kalliopi Pitarokoili, Helmar C. Lehmann, Alexander Grimm

Summary: This study investigates the current care of patients with immune-mediated polyneuropathies in specialized centers in Germany and provides important epidemiological insights. The findings suggest that the development of specific treatment and follow-up recommendations is necessary to ensure a uniform standard of patient care.

NERVENARZT (2023)

Article Clinical Neurology

Clinical and paraclinical features of small fiber neuropathy in Sjogren's syndrome

Tabea Seeliger, Henrike Neelke Dreyer, Janna Margaretha Siemer, Lena Boenig, Stefan Gingele, Maike Franziska Dohrn, Nils Prenzler, Diana Ernst, Torsten Witte, Thomas Skripuletz

Summary: Sjogren's syndrome is a potentially treatable cause of Small Fiber Neuropathy (SFN). This study found no significant differences in symptoms and cerebrospinal fluid parameters between SFN patients with and without Sjogren's syndrome. However, SFN patients with Sjogren's syndrome had lower intraepidermal nerve fiber densities, suggesting a different pathomechanism.

JOURNAL OF NEUROLOGY (2023)

Review Endocrinology & Metabolism

Influence of hormones in multiple sclerosis: focus on the most important hormones

Alireza Soleimani, Sajjad Ghane Ezabadi, Nora Moehn, Zahra Moghimi Esfandabadi, Zahra Khosravizadeh, Thomas Skripuletz, Maryam Azimzadeh

Summary: Hormonal imbalance is a significant factor in the severity of multiple sclerosis (MS). Hormone therapy has shown potential in regulating the immune system and protecting nerves in experimental studies. Thyroid, melatonin, and sex hormones have been found to improve neurological impairment by regulating the immune system, providing neuroprotection, and reducing oxidative stress. Understanding hormone therapy can lead to the identification of new molecular/cellular pathways in MS.

METABOLIC BRAIN DISEASE (2023)

Review Clinical Neurology

Performance of the revised 2017 McDonald criteria

Franz Felix Konen, Philipp Schwenkenbecher, Mike P. Wattjes, Thomas Skripuletz

Summary: This article reviewed and analyzed published studies comparing the use of the 2017 and 2010 McDonald criteria in terms of diagnostic performance. The results showed that the 2017 McDonald criteria diagnosed more patients with multiple sclerosis (MS) and enabled earlier diagnosis compared to the 2010 revision. The improvement was achieved through adjustments in imaging criteria and the introduction of oligoclonal bands as a diagnostic criterion.

NERVENARZT (2023)

Article Cardiac & Cardiovascular Systems

Premature stroke and cardiovascular risk in primary Sjogren's syndrome

Clara L. L. Zippel, Sonja Beider, Emelie Kramer, Franz F. F. Konen, Tabea Seeliger, Thomas Skripuletz, Stefanie Hirsch, Alexandra Jablonka, Torsten Witte, Kristina Sonnenschein, Diana Ernst

Summary: This study investigated specific risk factors for cardiovascular disease in patients with primary Sjogren's syndrome (pSS) and found that hypertension, hypercholesterolemia, diabetes, vasculitis, and Raynaud's phenomenon were associated with cardiovascular disease in pSS patients.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2022)

Article Clinical Neurology

Sjogren's syndrome with and without neurological involvement

Tabea Seeliger, Emelie Kramer, Franz Felix Konen, Nadine Zehrfeld, Sonja Beider, Nils Kristian Prenzler, Vega Goedecke, Torsten Witte, Thomas Skripuletz, Diana Ernst

Summary: By systematically evaluating neurological manifestations of primary Sjogren's syndrome, we found that patients with neurological involvement had different clinical characteristics compared to those without neurological involvement. Male sex, older age, hospitalization at first presentation, lower IgG levels, and higher eosinophil values were identified as independent predictors of neurological involvement in Sjogren's syndrome. These findings suggest that neurological involvement in Sjogren's syndrome has been underestimated, and intensified screening for neurologic involvement should be included in the diagnostic algorithm.

JOURNAL OF NEUROLOGY (2023)

Article Oncology

Monocyte chemoattractant protein 1 as a potential biomarker for immune checkpoint inhibitor-associated neurotoxicity

Nora Moehn, Susann Mahjoub, Laura Duzzi, Emily Narten, Lea Grote-Levi, Gudrun Koerner, Tabea Seeliger, Gernot Beutel, Benjamin-Alexander Bollmann, Thomas Wirth, Andre Huss, Hayrettin Tumani, Imke Grimmelmann, Ralf Gutzmer, Philipp Ivanyi, Thomas Skripuletz

Summary: Immune checkpoint inhibitors have shown great potential in treating cancer, but the occurrence of immune-related adverse events, particularly neurological events, is a concern. Currently, there are no reliable biomarkers to diagnose and predict these events.

CANCER MEDICINE (2023)

Article Medicine, General & Internal

Increased Alveolar Epithelial Damage Markers and Inflammasome-Regulated Cytokines Are Associated with Pulmonary Superinfection in ARDS

Konrad Peukert, Andrea Sauer, Benjamin Seeliger, Caroline Feuerborn, Mario Fox, Susanne Schulz, Lennart Wild, Valeri Borger, Patrick Schuss, Matthias Schneider, Erdem Gueresir, Mark Coburn, Christian Putensen, Christoph Wilhelm, Christian Bode

Summary: Acute respiratory distress syndrome (ARDS) is a life-threatening form of respiratory failure characterized by immune imbalance and damage to the alveolar epithelial and endothelial cells. Pulmonary superinfections occur in up to 40% of ARDS patients, leading to poor prognosis and increased mortality. This study aimed to identify a distinct pattern of pulmonary injury and pro-inflammatory response in ARDS patients who develop pulmonary superinfections. The analysis of serum and BALF samples revealed significantly increased levels of the cytokine IL-18 and the epithelial damage markers SP-D and sRAGE in ARDS patients with pulmonary superinfections. These findings suggest inflammasome activation and alveolar epithelial injury as potential biomarkers for identifying high-risk patients and developing targeted preventive strategies and personalized treatments.

JOURNAL OF CLINICAL MEDICINE (2023)

Review Clinical Neurology

Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis - a review of population-specific evidence from randomized clinical trials

Antonios Bayas, Monika Christ, Simon Faissner, Juliane Klehmet, Refik Pul, Thomas Skripuletz, Sven G. Meuth, SPMS Working Group

Summary: Although the understanding of SPMS is evolving, early detection of relapse-independent progression remains difficult. The term RMS includes RRMS and SPMS with relapses, and disease-modifying therapies approved for RMS or active SPMS are used. However, there are differences in efficacy and safety evidence between drugs approved for RMS and SPMS. Clinical trials have shown that siponimod and interferon-beta 1b s.c. have significant reductions in disability progression in SPMS populations, but data on other drugs approved for RMS are limited to small subgroups and the potential to reduce relapse-independent progression is unclear.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2023)

Meeting Abstract Clinical Neurology

A PHASE-3B OPEN-LABEL STUDY TO FURTHER INDIVIDUALIZE EFGARTIGIMOD TREATMENT OPTIONS FOR PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS

Kelly Gwathmey, Gregory Sahagian, Yessar Hussain, Marc Feinberg, Ali Habib, Thomas Skripuletz, Tobias Ruck, Edward Brauer, Deborah Gelinas, Sihui Zhao, Anna Bogatyreva, Renato Mantegazza

MUSCLE & NERVE (2022)

Meeting Abstract Clinical Neurology

CONTINUOUS AND FIXED-CYCLE DOSING OF INTRAVENOUS EFGARTIGIMOD FOR GENERALIZED MYASTHENIA GRAVIS: STUDY DESIGN OF ADAPT NXT

Kelly Gwathmey, Gregory Sahagian, Yessar Hussain, Marc Feinberg, Ali Habib, Thomas Skripuletz, Tobias Ruck, Michael Rivner, Fang Sun, Edward Brauer, Deborah Gelinas, Li Liu, Jana Podhorna, Renato Mantegazza

MUSCLE & NERVE (2022)

Article Clinical Neurology

IgG4-related hypertrophic pachymeningitis with tumor-like intracranial and intracerebral lesions

Majid Esmaeilzadeh, Mete Dadak, Oday Atallah, Nora Mohn, Thomas Skripuletz, Christian Hartmann, Rozbeh Banan, Joachim K. Krauss

Summary: IgG4-related hypertrophic pachymeningitis is a rare disease with diverse clinical manifestations, challenging diagnosis and treatment.

ACTA NEUROCHIRURGICA (2022)

No Data Available